TITLE

Pneumocystis carinii Pneumonia as a Complication of Immunosuppressive Therapy

AUTHOR(S)
Glück, T.; Geerdes-Fenge, H. F.; Straub, R. H.; Raffenberg, M.; Lang, B.; Lode, H.; Schölmerich, J.
PUB. DATE
August 2000
SOURCE
Infection;Aug2000, Vol. 28 Issue 4, p227
SOURCE TYPE
Academic Journal
DOC. TYPE
Report
ABSTRACT
Background: Patients receiving immunosuppressive therapy with corticosteroids and cytotoxic agents may develop opportunistic infections such as Pneumocystis carinii pneumonia (PCP). This indicates a severe T-cell defect, but so far there are no established criteria for identifying patients at risk. Patients and Methods: CD4+ and CD8+ T-lymphocyte counts were determined by flow cytometry in seven HIV- negative patients who developed PCP as a complication of immunosuppressive treatment. Results: CD4+ T-lymphocyte counts (T-helper phenotype) were less than 200/μl in all seven patients (mean 90.6/μl). The markedly reduced CD4 counts measured in these patients are similar to those observed in organ transplant recipients who developed PCP during immunosuppressive therapy for prevention of graft rejection and in HIV-positive patients with PCP as an AIDS-defining illness. Conclusion: Measuring CD4+ T-lymphocyte counts may be helpful in determining the risk of PCP not only in HIV- positive patients, but also in patients receiving immunosuppressive therapy. The risk of acqiring PCP seems to increase when CD4+ lymphocyte counts drop below 200/μl, regardless of the underlying disease.
ACCESSION #
18878595

 

Related Articles

  • Retroperitoneal Cryptococcoma in a Case of Disseminated Cryptococcosis on Antifungal Maintenance Therapy. Ferraioli, Giovanna; Cavanna, Caterina; Ricciardi, Manjula; Daffara, Silvio; Sangiovanni, Laura; Filice, Carlo; Barbarini, Giorgio // Current HIV Research;Jan2011, Vol. 9 Issue 1, p28 

    No abstract available.

  • Out of breath. Aronowitz, P. // Discover;Jan92, Vol. 13 Issue 1, p81 

    Relates the author's experiences with an AIDS patient suffering from the opportunistic infection `Pnuemocystis carinii' pnuemonia, who made a surprising recovery.

  • Are corticosteroids beneficial as adjunctive therapy for Pneumocystis pneumonia in AIDS? Kovacs, Joseph A.; Masur, Henry; Kovacs, J A; Masur, H // Annals of Internal Medicine;7/1/90, Vol. 113 Issue 1, p1 

    Editorial. Deals with treating pneumocystis pneumonia associated with AIDS. Occurrence of progressive desaturation after initiation of therapy; Use of corticosteroids as adjuvants to specific antipneumocystis therapy; Results of a placebo-controlled trial that assessed the effects of...

  • A 21-Day of Adjunctive Corticosteroid Use May Not Be Necessary for HIV-1-Infected Pneumocystis Pneumonia with Moderate and Severe Disease. Shibata, Satoshi; Nishijima, Takeshi; Aoki, Takahiro; Tanabe, Yoshinari; Teruya, Katsuji; Kikuchi, Yoshimi; Kikuchi, Toshiaki; Oka, Shinichi; Gatanaga, Hiroyuki // PLoS ONE;9/22/2015, Vol. 10 Issue 9, p1 

    Background: The current guidelines recommend 21-day adjunctive corticosteroid therapy for HIV-1-infected pneumocystis pneumonia patients (HIV-PCP) with moderate-to-severe disease. Whether shorter adjunctive corticosteroid therapy is feasible in such patients is unknown. Methods: We conducted a...

  • Pneumocystosis: a network survey in the Paris area 2003-2008. Magne, D.; Angoulvant, A.; Botterel, F.; Bouges-Michel, C.; Bougnoux, M.-E.; Bouree, P.; Chochillon, C.; Cornet, M.; Dannaoui, E.; Fekkar, A.; Galeazzi, G.; Yera, H.; Sarfati, C.; Roux, P. // European Journal of Clinical Microbiology & Infectious Diseases;May2011, Vol. 30 Issue 5, p673 

    The aims of this network group were to collect epidemiological data of PcP cases in 14 hospitals in the Paris area and to determine the Di-Hydro Pteroate Synthase (DHPS) genotypes, genetic markers for possible sulfamide resistance. From January 1, 2003 to December 31, 2008, 993 (mean 166/year)...

  • Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. Matsumura, Yasufumi; Shindo, Yuichiro; Iinuma, Yoshitsugu; Yamamoto, Masaki; Shirano, Michinori; Matsushima, Aki; Nagao, Miki; Ito, Yutaka; Takakura, Shunji; Hasegawa, Yoshinori; Ichiyama, Satoshi // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p76 

    Background: The number of patients with non-HIV Pneumocystis pneumonia (PCP) is increasing with widespread immunosuppressive treatment. We investigated the clinical characteristics of non-HIV PCP and its association with microbiological genotypes. Methods: Between January 2005 and March 2010,...

  • Plasma β-glucan for the Diagnosis of Pneumocystis Pneumonia in AIDS Patients. Blackburn, Brian G. // Infectious Disease Alert;Aug2011, Vol. 30 Issue 11, p126 

    Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection (OI) in AIDS patients. Laboratory diagnosis of this life-threatening infection is based primarily upon identifying P. jirovecii cysts in respiratory secretions, a technique that is variably sensitive and requires adequate...

  • Spectrums of opportunistic infections in HIV-infected patients at tertiary care hospital. Mundhra, Shashi Kumar H.; Mundhara, Krati S.; Trivedi, Nimisha Sunilbhai; Shah, Yash; Parmar, Hiren // International Archives of Integrated Medicine;Aug2015, Vol. 2 Issue 8, p38 

    Background: Literature on the spectrum of opportunistic disease in human immunodeficiency vims (HIV)-infected patients from developing countries is sparse. HIV-related opportunistic infections (OIs) continued to cause morbidity and mortality in HIV-infected individuals. Objectives: The objective...

  • Is It Safe to Discontinue Primary Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/μL? Furrer, Hansjakob // Clinical Infectious Diseases;9/1/2010, Vol. 51 Issue 5, p611 

    Background. Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count 1200 cells/μL. There...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics